Latest Randomized Clinical Trial Results of First Pro-Healing Stent Also
Featured at Annual Symposium
HONG KONG, Oct. 18 /PRNewswire/ -- OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is the subject of several sessions about innovation in interventional cardiology strategies and device design at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which is set for Oct. 20-25 at the Washington Convention Center in Washington, D.C.
The line-up of sessions that feature the first pro-healing stent, which is an alternative to drug-eluting stents, includes:
- Interventional Strategies and Adjunct Pharmacology in ACS and AMI;
Should Specialized DES for AMI be Developed? Early Experience with EPC
Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of
Cardiology, ISALA Klinieken, Hospital De Weezenlanden, Zwolle, The
Netherlands; 2:10 p.m. EDT on Oct. 21; Room 151B
- Innovative Devices and Futuristic Concepts: Novel Bare Metal and Drug-
Eluting Stents; The Genous Stent Coating with CD34 Antibodies to
Actively Capture Circulating EPCs: Design Parameters and Effects on
Healing and Thrombogenicity; Michael Kutryk, M.D., clinician scientist
and interventional cardiologist at St. Michael's Hospital, assistant
professor at the University of Toronto; Canada; 3:08 p.m. EDT on Oct.
21; Room 152A
In addition, the latest results from clinical trials of the Genous stent will be discussed by Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. Specifically, de Winter will present:
- Updates from the HEALING studies, AMC "Real World" registry and TRIAS
trial; 4:36 p.m. EDT on Oct. 21; Ballroom C, 3rd floor
- A late-breaking report of six-month clinical outcomes from the TRIAS HR
pilot study: a prospective, randomized trial comparing the Genous stent
and a paclitaxel-eluting stent in lesions at high risk for restenosis;
12:45 p.m. EDT on Oct. 22; Main Arena
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody- coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.
A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products in more than 60 countries. For more information, visit http://www.OrbusNeich.com.
Copyright©2007 PR Newswire.
All rights reserved